EMGEL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emgel, and what generic alternatives are available?
Emgel is a drug marketed by Altana and is included in one NDA.
The generic ingredient in EMGEL is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emgel
A generic version of EMGEL was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMGEL?
- What are the global sales for EMGEL?
- What is Average Wholesale Price for EMGEL?
Summary for EMGEL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,169 |
| DailyMed Link: | EMGEL at DailyMed |
US Patents and Regulatory Information for EMGEL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Altana | EMGEL | erythromycin | GEL;TOPICAL | 063107-001 | Aug 23, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
